Radiating for Two: Quantifying Radiation Exposure to Pregnant Urologists During Percutaneous Nephrolithotomy

Current occupational recommendations limit fetal radiation dose to 1 mSv. With increased gender diversity in urology, understanding radiation exposure during pregnancy is crucial. The purpose of this study was to determine surgeon uterine radiation dose during percutaneous nephrolithotomy (PCNL) and compare effectiveness of several radiation reduction strategies in a cadaver model.

Two cadavers were used to simulate the surgeon and the patient in a PCNL model. An ion chamber was placed behind the surgeon's anterior uterine wall to measure the radiation dose. Three radiation reduction methods were compared: pulsed fluoroscopy (1, 4, 8, 15, 30 pulses per second [pps]), low-dose (LD) fluoroscopy, and surgeon shielding (none, 0.35-, 0.50-, 0.70-mm lead equivalents). The average radiation dose per second was recorded for 20 trials per combination. Assuming 5 minutes of fluoroscopy per PCNL, the number of cases required to exceed the fetal occupational limit was determined.

Decreasing pulse frequency from 30 to 1 pps reduced the dose by 96% (P < .001). The LD setting decreased the dose by 56% (P < .001). A 0.35-mm lead apron resulted in a 94% dose reduction (P < .001), and the 0.50- and 0.70-mm lead aprons further reduced the dose by 12% and 47%, respectively. In conventional fluoroscopy settings of automatic exposure control and at 30 pps, a surgeon could perform 12 PCNLs using no lead or 189 PCNLs using a 0.35-mm lead apron before reaching the 1-mSv limit. In addition to shielding, using 1 pps with LD fluoroscopy further decreased radiation exposure, allowing over 6000 cases to be performed with < 1 mSv uterine radiation exposure.

Within the limitations of this cadaver study, these data support that high-volume pregnant surgeons using active radiation reduction techniques such as pulsed fluoroscopy, LD fluoroscopy, and appropriate shielding can maintain surgical volume with relatively low risk. Fetal dosimeter use with monthly monitoring is still encouraged to confirm safety throughout pregnancy.